For effective activation, tumor cryptic antigens must be presented on MHC Class I molecules, engaging cytotoxic CD8+ T cell responses via cross-presentation, primarily performed by specific APCs such as human BDCA3+, XCR1+, and CD141+ dendritic cells [48]. This evidence concerns the gene CD8A and neoplasm.